Cemdisiran

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name

Cemdisiran

DrugBank Accession Number

DB16121

Background

Cemdisiran is under investigation in clinical trial NCT03841448 (A Study of Cemdisiran in Adults With Immunoglobulin a Nephropathy (Igan)).

Type

Biotech

Groups

Investigational

Synonyms

Indication: Not Available
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings: Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Drug Interactions: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
3	Active Not Recruiting	Treatment	Paroxysmal Nocturnal Haemoglobinuria (PNH)	1
3	Recruiting	Treatment	Generalized Myasthenia Gravis	1
3	Recruiting	Treatment	Paroxysmal Nocturnal Haemoglobinuria (PNH)	1
2	Active Not Recruiting	Treatment	Berger Disease / Glomerulonephritis , IGA / IgA Nephropathy (IgAN)	1
2	Active Not Recruiting	Treatment	Paroxysmal Nocturnal Haemoglobinuria (PNH)	2
2	Withdrawn	Treatment	Atypical Hemolytic Uremic Syndrome (aHUS)	2
1	Completed	Treatment	Healthy Subjects (HS)	2

Drug created at December 15, 2020 18:13 / Updated at February 21, 2021 18:55